{"DataElement":{"publicId":"7620944","version":"1","preferredName":"Post-Transplant Lymphoproliferative Disorder Diagnosis Histologic Type","preferredDefinition":"A description of the post-transplant lymphoproliferative disorder histological type.","longName":"7620940v1.0:7620943v1.0","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"7620940","version":"1","preferredName":"Post-Transplant Lymphoproliferative Disorder Diagnosis","preferredDefinition":"Post-transplant lymphoproliferative disorder (PTLD) is a polyclonal (benign) or clonal (malignant) proliferation of lymphoid cells that develops as a consequence of immunosuppression in a recipient of a solid organ or bone marrow allograft. PTLDs comprise a spectrum ranging from early, Epstein-Barr virus (EBV)-driven polyclonal lymphoid proliferations to EBV-positive or EBV- negative lymphomas of predominantly B-cell or less often T-cell type. (WHO, 2001)_The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation.","longName":"5145475v1.0:2239981v1.0","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"5145475","version":"1","preferredName":"Post-Transplant Lymphoproliferative Disorder","preferredDefinition":"Post-transplant lymphoproliferative disorder (PTLD) is a polyclonal (benign) or clonal (malignant) proliferation of lymphoid cells that develops as a consequence of immunosuppression in a recipient of a solid organ or bone marrow allograft. PTLDs comprise a spectrum ranging from early, Epstein-Barr virus (EBV)-driven polyclonal lymphoid proliferations to EBV-positive or EBV- negative lymphomas of predominantly B-cell or less often T-cell type. (WHO, 2001)","longName":"C4727","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Post-Transplant Lymphoproliferative Disorder","conceptCode":"C4727","definition":"Post-transplant lymphoproliferative disorder (PTLD) is a polyclonal (benign) or clonal (malignant) proliferation of lymphoid cells that develops as a consequence of immunosuppression in a recipient of a solid organ or bone marrow allograft. PTLDs comprise a spectrum ranging from early, Epstein-Barr virus (EBV)-driven polyclonal lymphoid proliferations to EBV-positive or EBV- negative lymphomas of predominantly B-cell or less often T-cell type. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2D17B822-B220-FC17-E050-BB89AD4363BB","latestVersionIndicator":"Yes","beginDate":"2016-03-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-03-02","modifiedBy":"ONEDATA","dateModified":"2016-03-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2239981","version":"1","preferredName":"Diagnosis","preferredDefinition":"The process of identifying a disease by the signs and symptoms.","longName":"C15220","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Diagnosis","conceptCode":"C15220","definition":"The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F9FD4EEB-1C71-0B27-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-06-26","modifiedBy":"ONEDATA","dateModified":"2005-06-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BED7EDDA-466B-1515-E053-4EBD850A6C1E","latestVersionIndicator":"Yes","beginDate":"2021-03-31","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-03-31","modifiedBy":"MALUMK","dateModified":"2021-07-27","changeDescription":"Released 07/27/2021 KMM","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"7620943","version":"1","preferredName":"Post-Transplant Lymphoproliferative Disorder Histologic Type","preferredDefinition":"Post-transplant lymphoproliferative disorder (PTLD) is a polyclonal (benign) or clonal (malignant) proliferation of lymphoid cells that develops as a consequence of immunosuppression in a recipient of a solid organ or bone marrow allograft. PTLDs comprise a spectrum ranging from early, Epstein-Barr virus (EBV)-driven polyclonal lymphoid proliferations to EBV-positive or EBV- negative lymphomas of predominantly B-cell or less often T-cell type. (WHO, 2001)_Pertaining to the combined microscopic physical features of cells and their surrounding extracellular environment in tissues._Something distinguishable as an identifiable class based on common qualities.","longName":"7620943v1.0","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Unknown","valueDescription":"Unknown","ValueMeaning":{"publicId":"2960664","version":"1","preferredName":"Unknown","longName":"2960664","preferredDefinition":"Not known, not observed, not recorded, or refused.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unknown","conceptCode":"C17998","definition":"Not known, observed, recorded; or reported as unknown by the data contributor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"78485FBD-4C65-D67B-E040-BB89AD432E0E","latestVersionIndicator":"Yes","beginDate":"2009-11-13","endDate":null,"createdBy":"AHMEDS","dateCreated":"2009-11-13","modifiedBy":"KUMMEROA","dateModified":"2023-12-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BED7F14B-793E-1664-E053-4EBD850A4939","beginDate":"2021-03-31","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-03-31","modifiedBy":"ONEDATA","dateModified":"2021-03-31","deletedIndicator":"No"},{"value":"Polymorphic","valueDescription":"Polymorphic Post-Transplant Lymphoproliferative Disorder","ValueMeaning":{"publicId":"3249790","version":"1","preferredName":"Polymorphic Post-Transplant Lymphoproliferative Disorder","longName":"3249790","preferredDefinition":"A clonal B-cell lymphoproliferative disorder, characterized by destructive infiltration of lymph nodes and extranodal sites by a polymorphic B-cell infiltrate composed of small and medium sized lymphocytes, immunoblasts, and plasma cells, arising as a result of post-transplant immunosuppression therapy.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Polymorphic Post-Transplant Lymphoproliferative Disorder","conceptCode":"C7183","definition":"A clonal B-cell lymphoproliferative disorder arising as a result of post-transplant immunosuppression therapy. It is characterized by destructive infiltration of lymph nodes and extranodal sites by a polymorphic B-cell infiltrate composed of small and medium sized lymphocytes, immunoblasts, and plasma cells. In some cases, reduction of the immunosuppression therapy may lead to regression of the lesions. In other cases the lesions may progress to lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6DC37F6-CF95-75B6-E040-BB89AD430517","latestVersionIndicator":"Yes","beginDate":"2011-06-29","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-06-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BED7F14B-7952-1664-E053-4EBD850A4939","beginDate":"2021-03-31","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-03-31","modifiedBy":"ONEDATA","dateModified":"2021-03-31","deletedIndicator":"No"},{"value":"Monomorphic","valueDescription":"Monomorphic Post-Transplant Lymphoproliferative Disorder","ValueMeaning":{"publicId":"4722713","version":"1","preferredName":"Monomorphic Post-Transplant Lymphoproliferative Disorder","longName":"4722713","preferredDefinition":"A clonal lymphoproliferative disorder arising as a result of post-transplant immunosuppression therapy. It is characterized by destructive infiltration of lymph nodes and extranodal sites by a monotonous population of transformed lymphocytes or plasma cells.  It includes two variants: monomorphic B-cell and monomorphic T/NK cell post-transplant lymphoproliferative disorders.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Monomorphic Post-Transplant Lymphoproliferative Disorder","conceptCode":"C7233","definition":"A clonal lymphoproliferative disorder arising as a result of post-transplant immunosuppression therapy. It is characterized by destructive infiltration of lymph nodes and extranodal sites by a monotonous population of transformed lymphocytes or plasma cells.  It includes two variants: monomorphic B-cell and monomorphic T/NK cell post-transplant lymphoproliferative disorders.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F8AB028-C304-4E21-E050-BB89AD43094A","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BED7F14B-7966-1664-E053-4EBD850A4939","beginDate":"2021-03-31","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-03-31","modifiedBy":"ONEDATA","dateModified":"2021-03-31","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"7620942","version":"1","preferredName":"Post-Transplant Lymphoproliferative Disorder Histologic Type","preferredDefinition":"Post-transplant lymphoproliferative disorder (PTLD) is a polyclonal (benign) or clonal (malignant) proliferation of lymphoid cells that develops as a consequence of immunosuppression in a recipient of a solid organ or bone marrow allograft. PTLDs comprise a spectrum ranging from early, Epstein-Barr virus (EBV)-driven polyclonal lymphoid proliferations to EBV-positive or EBV- negative lymphomas of predominantly B-cell or less often T-cell type. (WHO, 2001):Pertaining to the combined microscopic physical features of cells and their surrounding extracellular environment in tissues.:Something distinguishable as an identifiable class based on common qualities.","longName":"C4727:C25526:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Post-Transplant Lymphoproliferative Disorder","conceptCode":"C4727","definition":"Post-transplant lymphoproliferative disorder (PTLD) is a polyclonal (benign) or clonal (malignant) proliferation of lymphoid cells that develops as a consequence of immunosuppression in a recipient of a solid organ or bone marrow allograft. PTLDs comprise a spectrum ranging from early, Epstein-Barr virus (EBV)-driven polyclonal lymphoid proliferations to EBV-positive or EBV- negative lymphomas of predominantly B-cell or less often T-cell type. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Histologic","conceptCode":"C25526","definition":"Pertaining to the combined microscopic physical features of cells and their surrounding extracellular environment in tissues.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BED7F14B-7917-1664-E053-4EBD850A4939","latestVersionIndicator":"Yes","beginDate":"2021-03-31","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-03-31","modifiedBy":"ONEDATA","dateModified":"2021-03-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BED7F14B-7928-1664-E053-4EBD850A4939","latestVersionIndicator":"Yes","beginDate":"2021-03-31","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-03-31","modifiedBy":"MALUMK","dateModified":"2021-07-27","changeDescription":"Released 07/27/2021 KMM","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"Specify type of PTLD","type":"Alternate Question Text","description":"Specify type of PTLD","url":null,"context":"NHLBI"},{"name":"Specify type of PTLD","type":"Application Standard Question Text","description":"Specify type of PTLD","url":null,"context":"NHLBI"},{"name":"What is the post-transplant l","type":"Preferred Question Text","description":"What is the post-transplant lymphoproliferative disorder histological type?","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BED73219-F9FD-27DD-E053-4EBD850A2282","latestVersionIndicator":"Yes","beginDate":"2021-03-31","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-03-31","modifiedBy":"MALUMK","dateModified":"2021-07-27","changeDescription":"Released. 07/27/2021 KMM; System generated def displayed as alt def.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}